Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurological Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SLTM drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLTM Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SLTM Products |
| Gene Delivery | SLTM Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SLTM Products |
| Benchmark Ab | Anti-SLTM Recombinant positive control for western blot and IHC. |
View SLTM Products |
| Validator | SLTM siRNA Set For knockdown verification and functional assays. |
View SLTM Products |
| Related Target A | SAFB Scaffold attachment factor B, homolog and interacting partner. |
View SAFB Products |
| Related Target B | SAFB2 SAFB-like transcription modulator partner. |
View SAFB2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Counter Screening (vs SAFB/SAFB2) | Homolog panel proteins strictly verified by mass spec and sequence analysis. |
| Intracellular Target Accessibility | High-titer Lentivirus for stable reporter cell line generation. |
| Lack of Controls | Recombinant positive control antibodies included. |
| False Positives in Knockdown | Validated siRNA included for specificity checks. |
Live SLTM R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLTM-related therapeutics is currently centered in the early discovery and preclinical stages, with an emphasis on its role as a transcriptional repressor and pro-apoptotic factor. As researchers map the RNA-binding protein landscape in oncology, SLTM is emerging as a potential node for targeted degradation (PROTACs) or synthetic lethality in specific tumor microenvironments. The next wave of R&D is targeting the disruption of its interaction with RNA polymerase II and other transcriptional machinery.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecules / PROTACs | Early Academic / Biotech Spin-offs | Solid Tumors | Selectivity Assay (Need High-Purity Proteins) |
| RNAi / ASO | Undisclosed Preclinical | Oncology, Neurodegeneration | Knockdown Validation (Need sequence-verified siRNA) |
| Gene Therapy | Preclinical Labs | Genetic Disorders | Expression Analysis (Need Benchmark Abs) |